Breast Cancer Metastasis and Drug Resistance

Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Expertsalso discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.

• bone metastasis
• breast cancer statistics
• breast cancer stem cells
• tamoxifen
• triple negative breast cancer
• antibacterial drug resistance

• Mitchell Cancer Institute, University of South Alabama, Mobile, USA

  Aamir Ahmad

Aamir Ahmad, PhD, is Assistant Professor of Oncologic Sciences at University of South Alabama’s Mitchell Cancer Institute, Mobile, AL, USA. He received his academic degrees from AMU, Aligarh, India and completed post-doctoral training at the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. His research interests include understanding the mechanisms of cancer drug resistance and metastasis in different cancers, with emphasis on the role of microRNAs, non-coding RNAs, epigenetics, exosomes, cancer stem cells and a personalized approach. He has authored 160 scientific research / review articles, edited/co-edited 8 books and serves as Expert Reviewer for scientific proposals submitted to 8 different funding agencies in Europe, Asia and Africa. He is the Founding Editor-in-Chief of the journal “Non-coding RNA Research”, Section Editor for the journal “Scientific Reports”, and is Section Editor for the journal “PLoS ONE”. He is also the Editor-in-Chief of the Elsevier series ‘Cancer Metastasis’.

Policies and ethics